<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PENICILLIN G PROCAINE</span><br/>(pen-i-sill'in)<br/><span class="topboxtradename">Crysticillin A.S., </span><span class="topboxtradename">Pfizerpen-AS, </span><span class="topboxtradename">Procaine Benzylpenicillin, </span><span class="topboxtradename">Wycillin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">beta-lactam antibiotic</span>; <span class="classification">natural penicillin</span><br/><b>Prototype: </b>Penicillin G potassium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>600,000 units/1 mL, 1,200,000 units/2 mL, 2,400,000 units/4 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting form of penicillin G. The procaine salt has low solubility and thus creates a tissue depot from which penicillin
         is slowly absorbed. Onset of action is slower and produces lower serum concentrations than equivalent doses of penicillin
         G potassium, but has longer duration of action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Same actions and antibacterial activity as for penicillin G potassium and is similarly inactivated by penicillinase and gastric
         acid.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Moderately severe infections due to penicillin G-sensitive microorganisms that are susceptible to low but prolonged serum
         penicillin concentrations. Commonly, uncomplicated <i>Pneumococcal</i> pneumonia, 1 d treatment of uncomplicated gonorrheal infections, and all stages of syphilis. May be used concomitantly with
         penicillin G or probenecid when more rapid action and higher blood levels are indicated.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to any of the penicillins, cephalosporins, or to procaine or any other "caine-type" local
         anesthetic; neonates; pregnancy (category B), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of or suspected allergy.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 600,0001,200,000 U once/d<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> 300,000 U once/d<br/><br/><span class="indicationtitle">Pneumococcal Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 600,000 U q12h<br/><br/><span class="indicationtitle">Uncomplicated Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 4,800,000 U divided between 2 different injection sites  at one visit preceded by 1 g of probenecid 30 min before injections<br/><br/><span class="indicationtitle">Syphilis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> Primary, secondary, latent: 600,000 U/d for 8 d; late latent, tertiary, neurosyphilis: 600,000 U/d for 1015 d<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> 500,0001,000,000 U/m<sup>2</sup> once/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Shake multiple-dose vial thoroughly before withdrawing medication to ensure uniform suspension of drug.</li>
<li>Use 20-gauge needle to avoid clogging.</li>
<li>Give IM deep into upper outer quadrant of gluteus muscle; in infants and small children midlateral aspect of thigh is generally
            preferred. Select IM site carefully. Accidental injection into or near major peripheral nerves and blood vessels can cause
            neurovascular damage.
         </li>
<li>Aspirate carefully before injecting drug to avoid entry into a blood vessel. Inadvertent IV administration reportedly has
            resulted in pulmonary infarcts and death.
         </li>
<li>Inject drug at a slow, but steady rate to prevent needle blockage. Give in two sites if the dose is very large. Rotate injection
            sites.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Procaine toxicity [e.g., mental disturbances (anxiety, confusion, depression, combativeness, hallucinations), expressed fear
      of impending death, weakness, dizziness, headache, tinnitus, unusual tastes, palpitation, changes in pulse rate and BP, seizures].
      Also see Penicillin G. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases renal elimination; may decrease efficacy of <span class="classification">oral contraceptives</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from IM site. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Duration:</span> 1520 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Hydrolyzed to penicillin in body. <span class="typehead">Elimination:</span> Excreted by kidneys within 2436 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain an exact history of patient's previous exposure and sensitivity to penicillins, cephalosporins, and to procaine, and
            other allergic reactions of any kind prior to treatment.
         </li>
<li>Test patient by injecting 0.1 mL of 12% procaine hydrochloride intradermally if sensitivity is suspected. Appearance
            of a wheal, flare, or eruption indicates procaine sensitivity.
         </li>
<li>Be alert to the possibility of a transient toxic reaction to procaine, particularly when large single doses are administered.
            The reaction manifested by mental disturbance and other symptoms (see <small>ADVERSE EFFECTS</small>) occurs almost immediately and usually subsides after 1530 min.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any skin reaction at the site of injection.</li>
<li>Report onset of rash, itching, fever, chills or other symptoms of an allergic reaction to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>